Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

Blood (2015) 126 (23): LBA-8.

https://doi.org/10.1182/blood.V126.23.LBA-8.LBA-8

Published: 2015

Journal Articles

Association Between Mitochondrial DNA Haplogroup and Myelodysplastic Syndromes

Jenny N Poynter, PhD, Michaela Richardson, Erica Langer, Anthony Hooten, Michelle A. Roesler, BS, Betsy A. Hirsch, PhD, Phuong L. Nguyen, MD, Adina Cioc, MD, Erica Warlick, MD, Julie A Ross, PhD

Blood (2015) 126 (23): 2885.

https://doi.org/10.1182/blood.V126.23.2885.2885

Published: 2015

Journal Articles

Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation

Claudio G Brunstein, MD, Corey S Cutler, MD MPH, Todd E. DeFor, MS, Thomas R. Spitzer, MD, Nelli Bejanyan, MD, Alfred L. Garfall, MD, Michael R. Verneris, MD, Yi-Bin Chen, MD, Erica Warlick, MD, Haesook T. Kim, PhD, Jeffrey S. Miller, MD, Joseph H. Antin, MD, Daniel J. Weisdorf, MD, Robert J Soiffer, MD, John E Wagner, MD, Karen K. Ballen, MD

Blood (2015) 126 (23): 2022.

https://doi.org/10.1182/blood.V126.23.2022.2022

Published: 2015

Journal Articles

Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age

Ehab Atallah, MD, Mary M. Horowitz, MD MS, Brent Logan, PhD, Min Chen, MS, Michael J. Boo, JD, Corey S Cutler, MD MPH, Joachim Deeg, MD, James L. Gajewski, MD, Dennis L. Confer, MD, Stephanie Farnia, MPH, Peter Greenberg, MD, Erica Warlick, MD, Daniel Weisdorf, MD, J. Douglas Rizzo, MD

Blood (2015) 126 (23): 193.

https://doi.org/10.1182/blood.V126.23.193.193

Published: 2015

Journal Articles

Bi-Specific Killer Cell Engagers (BiKEs) Signaling Through CD16 and Targeting CD33 (CD16 × CD33), Triggers Natural Killer (NK) Cell Cytotoxic and Cytokine Production Against Refractory Acute Myeloid Leukemia (AML)

Andres Wiernik, MD, Bree Foley, PhD, Bin Zhang, Michael R. Verneris, MD, Erica Warlick, MD, Julie A. Ross, PhD, Louis M. Weiner, MD, Daniel J. Weisdorf, MD, Daniel A Vallera, PhD, Jeffrey S. Miller, MD

Blood (2012) 120 (21): 256.

https://doi.org/10.1182/blood.V120.21.256.256

Published: 2012

Journal Articles

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

Blood (2012) 119 (17): 4083–4090.

https://doi.org/10.1182/blood-2012-02-409763

Published: 2012

Journal Articles

Chronic Myelomonocytic Leukemia and Related Disorders Provide Particular Disease-Specific Challenges to Effective Bone Marrow Transplant: a Multicenter Experience.

Steven E. McCormack, MD, Yan Zhang, MS, Ramon V. Tiu, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Ronald Sobecks, MD, Javier Bolanos-Meade, MD, Michael A McDevitt, MD, PhD, Erica Warlick, MD

Blood (2010) 116 (21): 4561.

https://doi.org/10.1182/blood.V116.21.4561.4561

Published: 2010

Journal Articles

Monosomal Karyotype Provides Better Prognostic Prediction After Allogeneic Stem Cell Transplantation in AML Patients.

Betul Oran, MD, MS, Michelle Dolan, MD, Linan Ma, M.S.P.H., Claudio Brunstein, MD, PhD, Erica Warlick, MD, Daniel J. Weisdorf, MD

Blood (2009) 114 (22): 525.

https://doi.org/10.1182/blood.V114.22.525.525

Published: 2009

Journal Articles

Myeloablative Allogeneic Bone Marrow Transplantation (AlloBMT) with T Cell Depletion (TCD) and Post-Transplant GM-CSF for Patients with High Risk MDS.

Erica Warlick, MD, Richard J. Jones, MD, Elizabeth Garrett-Mayer, PhD, Paul O’Donnell, MD, PhD, B. Douglas Smith, MD

Blood (2006) 108 (11): 5309.

https://doi.org/10.1182/blood.V108.11.5309.5309

Published: 2006

NARROW

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

Association Between Mitochondrial DNA Haplogroup and Myelodysplastic Syndromes

Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation

Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age

Bi-Specific Killer Cell Engagers (BiKEs) Signaling Through CD16 and Targeting CD33 (CD16 × CD33), Triggers Natural Killer (NK) Cell Cytotoxic and Cytokine Production Against Refractory Acute Myeloid Leukemia (AML)

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

Chronic Myelomonocytic Leukemia and Related Disorders Provide Particular Disease-Specific Challenges to Effective Bone Marrow Transplant: a Multicenter Experience.

Monosomal Karyotype Provides Better Prognostic Prediction After Allogeneic Stem Cell Transplantation in AML Patients.

Myeloablative Allogeneic Bone Marrow Transplantation (AlloBMT) with T Cell Depletion (TCD) and Post-Transplant GM-CSF for Patients with High Risk MDS.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only